Iterion Therapeutics announced that two abstracts featuring its first-in-class TBL1 inhibitor, tegavivint, will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have increased year by year. HCC research has increasingly focused on ...
Morning Overview on MSN
Researchers find some cancer drugs work differently than their stated targets
As of spring 2026, a cancer drug that has spent years in clinical development as a Wnt/beta-catenin pathway blocker has been ...
A Wnt/β-catenin pathway agonist under development by Surrozen appears to be effective against idiopathic pulmonary fibrosis (IPF) in mouse models, according to new data. The results, published April 2 ...
WNT pathway alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–driven and disparity-aware precision oncology analysis. Longitudinal clinical validation of the ...
Researchers are rethinking how we target bowel cancer growth pathways, using patient-derived organoids to identify whether ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results